Synopsis
We are developing novel imaging tracers for rapid and noninvasive assessment of bacterial infections and to study antimicrobial pharmacokinetics.tuberculosis, infection, bacteria, PET, MRI, pharmacokinetics
Current tools to
diagnose and monitor infections are dependent upon sampling suspected sites, and
then performing culture or molecular techniques. This approach is invasive,
often dangerous, time consuming, and is subject to incorrect sampling and
contamination. Molecular imaging is a powerful, noninvasive tool that can rapidly
provide three-dimensional views of disease processes deep within the body. Moreover,
it has the fundamental advantage (with significant potential for clinical
translation), to conduct noninvasive longitudinal assessments of the same patient.
We have pioneered the development of molecular imaging specific for infectious
diseases. Our overall goals are to
develop novel imaging tracers for rapid and noninvasive assessment of bacterial
infections and to study antimicrobial pharmacokinetics. These technologies are
an emerging field of research, overcome several fundamental limitations of
current tools, and will have a broad impact on both basic research and patient
care. Beyond diagnosis and monitoring disease, these technologies will also provide
a uniform cross-species platform for animal studies; allow unique insights into
understanding disease pathogenesis; and expedite bench-to-bedside translation
of new therapeutics. Finally, since molecular imaging is readily available for
humans, validated tracers will become valuable tools for clinical applications,
and for enabling personalized medicine for infectious diseases.
Acknowledgements
These studies were funded by the National Institutes of
Health Director’s Transformative Research Award R01-EB-020539 (S.K.J.), NIH Director’s New
Innovator Award DP2-OD-006492 (S.K.J.), and NIH R01-HL-116316
(S.K.J.).References
1. Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM,
Pokkali S, MacDonald EM, Klunk M, Mease RC, Pomper MG, Jain SK. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol
positron emission tomography. Sci Transl Med. 2014 Oct 22; 6(259):259ra146. doi:
10.1126/scitranslmed.3009815. [Cover
article].
2. Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC,
Foss CA, Pomper MG, Jain SK.
Radioiodo-DPA-713 Imaging Correlates with Bactericidal Activity of Tuberculosis
Treatments in Mice. Antimicrob Agents Chemother. 2015 Jan;59(1):642-9. doi:
10.1128/AAC.04180-14.
3. DeMarco VP, Ordonez AA, Klunk M, Prideaux
B, Wang H, Zhuo Z,
Tonge PJ, Dannals RF, Holt DP, Lee CK,
Weinstein EA, Dartois V, Dooley KE, Jain SK. Determination of 11C-Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice
Using Dynamic Positron Emission Tomography Bioimaging. Antimicrob Agents
Chemother. 2015 Sep;59(9):5768-74.
4. Salazar-Austin N, Ordonez AA, Hsu A, Benson JE, Mahesh
M, Menachery E, Razeq JH, Salfinger M, Starke JR, Milstone AM, Parrish N,
Nuermberger EL, Jain SK. Extensively
Drug-Resistant Tuberculosis in a Young Child after Travel to India. Lancet
Infect Dis. 2015;15:1485-91.
5. Xu J, DeMarco VP,
Pokkali S, Ordonez AA, Klunk M, Penet MF, Bhujwalla Z, van Zijl PC, Jain SK. In situ pH effects within Mycobacterium tuberculosis Infected Mice
revealed by UTE-CEST MRI. ISMRM. Toronto, Canada 2015.